AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04409821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-delivered psychological intervention
Description: The intervention consists of two (or one, if preferred by caregivers) weekly tele-sessions during the ICU stay, lasting up to 30 minutes, and two sessions in the month after discharge from or death in the ICU. Sessions will be conducted via phone-calls or video-conferencing. Therapists will 1) validate caregivers' subjective experience, 2) normalize and psychoeducate about emotional reactions, and 3) offer emotion regulation drawing on contemporary cognitive treatment packages of decentering, acceptance and emotion tolerance. Sessions for bereaved caregivers will include psycho-education about grief, assessment of risk for adverse outcomes and information about available support, if needed. The intervention will be performed based on an intervention manual. The content of the intervention will be continually adapted and tailored to the needs of the participating caregivers by involving all caregivers in co-creating the intervention trough brief post-session interviews.
Study NCT03108248 — intervention group
Intervention type: DRUG
Intervention: ethiodized oil; doxorubicin;Gelfoam;
Description: Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
Study NCT03108248 — intervention group
Intervention type: DEVICE
Intervention: stent; idoine-125
Description: In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
Study NCT04776967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Compression Profile
Description: A total of 4 randomized hyperbaric treatment compression profiles (accepted standards of care) will be alternated over the patients course of treatment on a daily basis daily to the prescribed treatment depth.
Study NCT02857010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic mesenchymal stem cells
Description: Cell therapy
Study NCT02857010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Serum without stem cells
Study NCT02041845 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60 Gy in 40 fractions
Description: 3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
Study NCT03441373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily during 5 days.
Study NCT03143712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
Study NCT03656718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (Subcutaneous) Specified dose on specified days
Study NCT00280735 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
Study NCT00280735 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: 75 mg/m² intravenously, once, every 3 weeks
Study NCT01452243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium suplementation
Description: The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
Study NCT02201004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TOFOGLIFLOZIN CSG452
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02201004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOFOGLIFLOZIN CSG452
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02201004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02201004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02201004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT04385017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 patients
Description: It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
Study NCT00218933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise training
Description: 12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
Study NCT00218933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity exercise training
Description: 12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
Study NCT00578591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver.
Study NCT01609790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00131937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT04381793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recovery Factors
Description: Porcine serum amino acid/peptide
Study NCT04194138 — intervention group
Intervention type: PROCEDURE
Intervention: Index or spine revision surgery for complex adult spinal deformity
Description: Surgical interventions will be patient specified by treating surgeon.
Study NCT01685320 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forces applied by laryngoscope
Description: Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
Study NCT02320734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium given continuously to reach deep neuromuscular block
Study NCT03679234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine infant formula
Description: Routine infant formula with probiotic
Study NCT04107532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality Therapy and Imagination Exposure Therapy
Description: Virtual Reality Therapy and Imagination Exposure Therapy
Study NCT02553291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE
Study NCT02553291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT01071421 — intervention group
Intervention type: DEVICE
Intervention: abbreviated polysomnography
Description: Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
Study NCT01171794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
Study NCT01171794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical number of visually identical tasteless pills as ibuprofen arm
Study NCT03005717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202
Study NCT03005717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for LIPO-202
Description: Lyophile manufactured to mimic LIPO-202 lyophile.
Study NCT03441620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: strawberries
Description: Freeze-dried strawberry powder
Study NCT03441620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control powder
Description: Control powder matched for fiber and strawberries
Study NCT04409327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTB101
Description: Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks
Study NCT04409327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo once daily for 4 weeks
Study NCT02366026 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IR103
Description: REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
Study NCT02366026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IR103
Description: REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
Study NCT04339621 — intervention group
Intervention type: DEVICE
Intervention: LiverMultiscan
Description: The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores
Study NCT04798430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: PCSK9 inhibitor
Study NCT01240109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: * propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml
Study NCT01675518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral
Study NCT00710840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Total Knee Arthroplasty [TKA Min]
Description: TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
Study NCT00710840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty (TKA) Traditional
Description: TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
Study NCT01785199 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Head elevation by an automatic adjustable bed
Description: The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
Study NCT01785199 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Head elevation by an automatic adjustable bed
Description: The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
Study NCT04021602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 6 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
Study NCT04021602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding Education
Description: Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
Study NCT04021602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
Study NCT04021602 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
Study NCT03784755 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ablative Radiation Therapy
Description: Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
Study NCT03784755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
Study NCT03784755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
Study NCT03707938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO
Study NCT03707938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Consolidation Therapy
Description: Undergo local consolidative therapy
Study NCT02027246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
Study NCT02524262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Slow-release L-cysteine
Description: Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
Study NCT02524262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Slow-release L-cysteine
Description: Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
Study NCT02009111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple CARE for Parents
Description: Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
Study NCT02009111 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Couple CARE for Parents
Description: Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 - 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 - 12 hrs).
Study NCT00478504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
Study NCT00478504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomifene citrate
Description: Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
Study NCT00605969 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Motion analysis
Description: Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
Study NCT00605969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Motion analysis
Description: Participants will undergo a motion analysis procedure: a dynamic assessment of the movement in their hip.
Study NCT00605969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Participants will undergo computed tomography (CT) scan of their hip.
Study NCT00605969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Participants will undergo computed tomography (CT) scan of their hip.
Study NCT03226366 — intervention group
Intervention type: OTHER
Intervention: Immediate evaluation by multidisciplinary team
Description: Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
Study NCT02402556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
Study NCT02402556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOCEP
Description: Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
Study NCT01484717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management for smoking abstinence
Description: Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
Study NCT01484717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine
Description: Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
Study NCT01484717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine
Description: Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
Study NCT01484717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Participants receive brief twice weekly telephone counseling.
Study NCT01484717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: Participants receive brief twice weekly telephone counseling.
Study NCT01667523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 1.5 mg capsaicin administered intraduodenally
Study NCT01609790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT01667523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde
Description: 70 mg per intervention administered intraduodenally
Study NCT01667523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline
Study NCT05206669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
Study NCT05206669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
Study NCT01961765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib